Advagraf + Prograf

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Adherence to Medication Regime

Conditions

Adherence to Medication Regime

Trial Timeline

May 9, 2014 → Mar 31, 2020

NCT ID

NCT02251691

About Advagraf + Prograf

Advagraf + Prograf is a approved stage product being developed by Astellas Pharma for Adherence to Medication Regime. The current trial status is unknown. This product is registered under clinical trial identifier NCT02251691. Target conditions include Adherence to Medication Regime.

What happened to similar drugs?

3 of 4 similar drugs in Adherence to Medication Regime were approved

Approved (3) Terminated (0) Active (1)

🔄Tacrolimus BID + Advagraf QDAstellas PharmaPhase 3

✅TasP using ART regimen as per Benin guidelines + PrEP using TruvadaGilead SciencesApproved

✅Vitamin D SupplementGilead SciencesApproved

✅ziprasidonePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03216447	Approved	UNKNOWN	Nov 23, 2017	Sep 30, 2025	Liver Transplantation
NCT02251691	Approved	UNKNOWN	May 9, 2014	Mar 31, 2020	Adherence to Medication Regime
NCT02268201	Approved	Terminated	Jul 23, 2013	Mar 31, 2015	Kidney Transplant Recipients
NCT01332201	Phase 2	Completed	Jul 1, 2011	Nov 1, 2013	Heart Transplantation
NCT01742676	Approved	Completed	Apr 1, 2011	Apr 1, 2013	Renal Transplantation

Competing Products

4 competing products in Adherence to Medication Regime

See all competitors

Product	Company	Stage	Hype Score
Tacrolimus BID + Advagraf QD	Astellas Pharma	Phase 3	36
TasP using ART regimen as per Benin guidelines + PrEP using Truvada	Gilead Sciences	Approved	43
Vitamin D Supplement	Gilead Sciences	Approved	43
ziprasidone	Pfizer	Approved	43